HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
NCT02536469
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
HuMax-IL8
Sponsor
Bristol-Myers Squibb
Collaborators
[object Object]